Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change
This article was originally published in Pharmaceutical Approvals Monthly
Upheaval in the chronic kidney disease market ranging from FDA’s ongoing re-evaluation of the safety of erythropoietin stimulating agents to impending major changes in Medicare reimbursement for dialysis patients is resulting in a chain reaction of adjustments in drug development strategies.
You may also be interested in...
The $18-per-share offer represents a 25% premium over AMAG's stock price as of Aug. 2, but it's not enough to return the anemia drug maker's valuation to the days just before it unveiled the Allos deal on July 20.
The prospect of anemic Medicare compensation for Feraheme (ferumoxytol) may have pushed the company to promote the drug in ways that FDA's advertising reviewers think is illegitimate.
Company set to price drug up to 20% below Genzyme's market leading Renvela/Renagel franchise, and ponders impact of new Medicare bundling regime for phosphate binders used in end-stage renal disease.